Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATP8B1
REST API REST API
Homo sapiens
ATP8B1 is differentially expressed in 270 experiments: 140 organism parts: liver, prostate, ... (138 more);, 162 disease states: normal, Parkinson's disease, ... (160 more);, 96 cell types 409 cell lines 37 compound treatments and 75 other conditions.
Synonyms PFIC1, BRIC, PFIC, ATPIC, FIC1
Orthologs Atp8b1 (Rattus norvegicus)   ATP8B1 (Danio rerio)   ATP8B1 (Bos taurus)   ATP8B1 (Gallus gallus)   Atp8b1 (Mus musculus)   CG14741 (Drosophila melanogaster)   XB-GENE-965605 (Xenopus laevis)   ATP8B1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism, negative regulation of transcription, DNA-dependent, bile acid metabolic process, membrane, ATPase activity, metabolic process, metal ion binding, cation transport, phospholipid transport, membrane fraction, phospholipid-translocating ATPase activity, ATP binding, magnesium ion binding, integral to plasma membrane, hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances, nucleotide binding, ATP biosynthetic process, apical plasma membrane, integral to membrane, hydrolase activity, transmembrane transport, catalytic activity, ATP catabolic process, bile acid and bile salt transport, brush border membrane, ion transmembrane transport
InterPro Term ATPase_P-typ_Plipid-transl, Dehalogen-like_hydro, ATPase_P-typ_ion-transptr, ATPase_P-typ_ATPase-assoc-dom
UniProt Accession O43520
Gene-Disease Assocation CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 1; PFIC1, CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 1; BRIC1, CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY; ICP
Search EB-eye ENSG00000081923
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-22541, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
MDA468
2
E-MEXP-440, E-MTAB-62
BT474
2
E-MTAB-37, E-MEXP-440
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HL-60
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MOLT4
2
E-MTAB-62, E-MTAB-37
403 more value(s).


Cell type

studied in E-GEOD-492, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (43 experiments)

Factor Value U/D Experiments
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
CD8+ T cell
2
E-AFMX-5, E-TABM-145
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
mononuclear
2
E-GEOD-13987, E-GEOD-26672
stromal cell
2
3
E-GEOD-1460, E-GEOD-3998, E-MEXP-2034, E-MEXP-1121, E-GEOD-10797 ... (5 experiments)
epithelial cell
1
2
E-MEXP-2034, E-MEXP-1121, E-GEOD-10797
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (52 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
3
E-GEOD-2466, E-MTAB-37, E-GEOD-6691
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
obesity
2
E-MTAB-62, E-GEOD-2508
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
T-cell acute lymphoblastic leukemia
2
E-GEOD-1577, E-MTAB-37
156 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-6907, E-GEOD-5824, E-TABM-868, E-GEOD-6462, ... (23 experiments)

Factor Value U/D Experiments
none
4
5
E-GEOD-20719, E-TABM-868, E-MEXP-1601, E-GEOD-412, E-GEOD-5824, ... (9 experiments)
actinomycin D
1
E-GEOD-6400
HMB-PP (phosphoantigen)
1
E-MEXP-1601
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
unknown
1
E-GEOD-7307
ponasterone A
1
E-GEOD-3113
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-22513, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MTAB-69, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-5824, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922, E-TABM-147

Processing time: 0.428 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM